Report : Europe PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Real-Time PCR (qPCR), Multiplex PCR, Traditional PCR, Digital PCR, Reverse-Transcriptase (RT-PCR), and Others), Product Type (Reagents & Kits, Instruments, and Others), Infection Type (Bacterial Infections, Viral Infections, and Fungal & Other Pathogens); End User (Hospitals, Physician Clinics, Clinical Laboratories, Academic & Research Institutions, Biotech & Pharma Companies, and Others), and Country
The real-time PCR (qPCR) segment by type is estimated to lead the market growth during the forecast period.
According to a new market research study of “Europe PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Product Type, Infection Type, End User and Country.” The Europe PCR for respiratory infection diagnostics market is expected to reach US$ 2,432.46 million by 2028 from US$ 1,241.01 million in 2021; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights trends prevailing in the Europe PCR for respiratory infection diagnostics market and the factors driving market along with those that act as hindrances. The growth of the market is determined due to some of the key driving factors, such as increasing burden of chronic respiratory diseases (CRDs) and growing developments in PCR testing, are expected to propel the growth of the market. However, availability of alternative assays is the major factor hindering the market growth.
Chronic respiratory diseases (CRDs) are among the leading causes of morbidity globally due to the heavy consumption of tobacco. For instance, according to the National Health Services, in England, nearly one in five people is affected by a respiratory disease, and respiratory diseases is the third leading cause of deaths. The burden of CRDs is expected to increase in the future due to poor air quality, addiction to smoking, and rise in geriatric population is more prone to COPD and lung cancer. Moreover, programs initiated in the countries to improve treatment and support the people living with respiratory diseases are likely to increase the demand for PCR for the diagnosis of respiratory diseases. This will lead to the market growth during the forecast period. PCR testing is the gold standard for detecting respiratory infectious diseases, including SARS-CoV-2. Also, the growing developments in PCR are not limited to the COVID-19 testing. The continuous technological developments have allowed researchers to develop advanced PCR techniques at a reduced cost and limit their complexities. In addition, PCR testing is significantly used in institutions such as nursing homes, chronic care facilities, and hospitals for identifying influenza virus infection that causes respiratory outbreaks. Therefore, various companies are offering PCR kits that can detect the presence of pathogens that cause respiratory diseases. Apart from the increasing incidence of acute and chronic respiratory diseases, other factors such as environmental and climatic conditions, air pollution, and discoveries of novel bacteria, viruses, and pathogens are likely to serve as vital growth opportunities for PCR testing for respiratory infection diagnostics in the future.
The European economy is seriously hit due to the exponential growth of COVID-19 cases in the region. The rising occurrence rate of coronavirus results in increased stress on the region's healthcare system, which is also rising the demand for diagnostic tests in its healthcare system, supporting the expansion of the sector in this region. Several manufacturers are developing advanced PCR test kits and systems for the detection of COVID-19 virus. As the coronavirus increases, millions of people will need testing. Thus, high throughput molecular testing is expected to play a central role in the future management of the COVID-19 pandemic. Therefore, the need for early detection of respiratory infection diseases is thought to be propelling the European PCR for respiratory infection diagnostics market growth during the forecast period.
The Europe PCR for respiratory infection diagnostics market, by type, is segmented into real time PCR (qPCR), traditional PCR, reverse-transcriptase (RT-PCR), digital PCR, multiplex PCR, and others. Based on product type, the Europe PCR for respiratory infection diagnostics market is segmented into reagents and kits, instruments, and others. Based on infection type, the Europe PCR for respiratory infection diagnostics market is segmented into bacterial infection, viral infection, and fungal & other pathogens. The bacterial infection segment is further divided into bordetella, streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydophila pneumoniae, legionella and others. Additionally, the viral infection segment is further bifurcated into rhinoviruses, influenza virus, severe acute respiratory syndrome (sars) cov-2 virus, respiratory syncytial virus (rsv), adenovirus, enterovirus, parainfluenza, human metapneumovirus (hmpv) and others. Further, based on end user, the Europe PCR for respiratory infection diagnostics market is segmented into hospitals, physician clinics, clinical laboratories, academic and research institutions, biotech and pharma companies, and others. Geographically, the Europe PCR for respiratory infection diagnostics market can be segmented into France, Spain, Italy, Germany, U.K and Rest of Europe.
Abbott, F. HOFFMANN-LA ROCHE LTD, Hologic, Inc., BD, BIO-RAD LABORATORIES INC., bioMerieux SA, QIAGEN, Thermo Fisher Scientific Inc., AusDiagnostics and Seegene Incare among the leading companies operating in the Europe PCR for respiratory infection diagnostics market.
Contact Person: Sameer Joshi
Email Id: email@example.com